SELLAS Life Sciences gains 38.8% in a week as Phase 3 trial nears readout
#SELLAS Life Sciences shares have experienced a major upward run as investors anticipate clinical trial results.
#The stock rose 38.8% in a week to close at $7.29 on May 18, up from $5.25 on May 11.
#This move follows Q1 earnings and confirmation that its Phase 3 REGAL trial in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis.